Bioengineering, Год журнала: 2025, Номер 12(4), С. 430 - 430
Опубликована: Апрель 19, 2025
Doxorubicin (DOX) is one of the most powerful chemotherapy drugs used to treat different kinds cancer. However, its usage has been limited by typical side effects and drug resistance, particularly cardiotoxicity. According studies, a more effective promising method conjugate it or entrap in biocompatible nanoparticles. Compared free DOX traditional formulations, nanoparticles using specific processes techniques can improve stability, minimize premature release at untargeted locations, lower systemic toxicity. This review explains how various nanocarriers target tumor therapeutic efficacy while reducing negative DOX.
Язык: Английский